Nik Sheng Ding (Nik S Ding, N S Ding, Nik Ding)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2015-2024
Publications (10 Years): 23

Top Venues

Alimentary pharmacology & therapeutics

Journal of Crohn's & colitis

Scandinavian journal of gastroenterology

JGH open : an open access journal of gastroenterology and hepatology

Imperial College

University of Melbourne (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Imperial College Jul 01 2014

United Kingdom

Clinical lecturer :: Medicine

Education History

University of Melbourne

Australia

PHD

Publications

John David Chetwood, Nik Sheng Ding
Letter: Ulcerative proctitis-A step towards addressing the knowledge gap, and a call for greater detail, in trial data. Alimentary pharmacology & therapeutics (2024)
John David Chetwood, Nik Sheng Ding
Letter: Third-line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions. Alimentary pharmacology & therapeutics 60 (2) (2024)
John David Chetwood, Nik Sheng Ding
Letter: Third-line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions. Alimentary pharmacology & therapeutics (2024)
John David Chetwood, Nik Sheng Ding
Letter: Third-line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions. Alimentary pharmacology & therapeutics 60 (2) (2024)
Daniel Tassone, Imogen Hartley, Nik Sheng Ding
Letter: Muscle thickness measurement using ultrasound-A step closer to the use of body composition analysis in the management of inflammatory bowel disease. Alimentary pharmacology & therapeutics 58 (7) (2023)
Daniel Tassone, Robert Gilmore, Tanya Lee, Nik Sheng Ding
Letter: diagnostic delay in inflammatory bowel disease. Alimentary pharmacology & therapeutics 57 (10) (2023)
Imogen Hartley, Tanya Lee, Nik Sheng Ding
Editorial: improving the use of Montreal classification through a bidirectional approach. Alimentary pharmacology & therapeutics 58 (1) (2023)
Nurulamin M Noor, Paula Sousa, Dominik Bettenworth, Fernando Gomollón-Bel, Triana Lobaton, Peter Bossuyt, Maria Jose Casanova, Nik Sheng Ding, Gabriele Dragoni, Federica Furfaro, Patrick F van Rheenen, Maria Chaparro, Francisco Javier García-Alonso, Edouard Louis, Konstantinos Papamichael
ECCO Topical Review on Biological Treatment Cycles in Crohn's Disease. Journal of Crohn's & colitis (2023)
Daniel Tassone, Robert Gilmore, Tanya Lee, Nik Sheng Ding
Letter: diagnostic delay in inflammatory bowel disease. Alimentary pharmacology & therapeutics 57 (10) (2023)
Natalie Yu, Danujan Sriranganathan, Gareth J Walker, Aleksejs Sazonovs, Helen Wilding, Christopher Roberts, Nicholas A Kennedy, Tariq Ahmad, Ray K Boyapati, Nik Sheng Ding, Jonathan P Segal
Prevalence of NUDT15 genetic variants and incidence of thiopurine-induced leukopenia in Inflammatory Bowel Disease: A systematic review and meta-analysis. Journal of Crohn's & colitis (2023)
Robert Gilmore, Daniel Tassone, Nik Sheng Ding
Letter: tofacitinib in the real world - do clinical trial data stand up? Alimentary pharmacology & therapeutics 57 (6) (2023)
Daniel Tassone, Imogen Hartley, Nik Sheng Ding
Letter: Combatting sarcopenia to improve clinical outcomes in inflammatory bowel disease. Alimentary pharmacology & therapeutics 58 (3) (2023)
Daniel Tassone, Robert Gilmore, Tanya Lee, Nik Sheng Ding
Letter: diagnostic delay in inflammatory bowel disease. Alimentary pharmacology & therapeutics 57 (10) (2023)
Daniel Tassone, Robert Gilmore, Tanya Lee, Nik Sheng Ding
Letter: diagnostic delay in inflammatory bowel disease. Alimentary pharmacology & therapeutics 57 (10) (2023)
Nik Sheng Ding, Daniel Tassone, Ibrahim Al Bakir, Kyle Wu, Alexander J Thompson, William R Connell, George Malietzis, Phillip Lung, Siddharth Singh, Chang-Ho Ryan Choi, Simon Gabe, John T Jenkins, Ailsa Hart
Systematic Review: The Impact and Importance of Body Composition in Inflammatory Bowel Disease. Journal of Crohn's & colitis 16 (9) (2022)
Daniel Tassone, Siddharth Singh, Nik Sheng Ding
Editorial: impact of body mass index on clinical outcomes in patients with ulcerative colitis treated with tofacitinib. Alimentary pharmacology & therapeutics 54 (2) (2021)
Vandita Y Mattoo, Chamara Basnayake, William R Connell, Nik Sheng Ding, Michael A Kamm, Mark Lust, Ola Niewiadomski, Alexander Thompson, Emily K Wright
Systematic review: efficacy of escalated maintenance anti-tumour necrosis factor therapy in Crohn's disease. Alimentary pharmacology & therapeutics 54 (3) (2021)
Tanya Lee, Eric Yong, Nik Sheng Ding
Radiological outcomes in perianal fistulizing Crohn's disease: A systematic review and meta-analysis. JGH open : an open access journal of gastroenterology and hepatology 4 (3) (2019)
Jonathan P Segal, Lawrence Penez, Soad Mohsen Elkady, Guy H T Worley, Simon D McLaughlin, Benjamin Harvey Mullish, Mohammed N Quraishi, Nik Sheng Ding, Tamara Glyn, Kesavan Kandiah, Mark A Samaan, Peter M Irving, Omar D Faiz, Susan K Clark, Ailsa L Hart
Long term outcomes of initial infliximab therapy for inflammatory pouch pathology: a multi-Centre retrospective study. Scandinavian journal of gastroenterology 53 (9) (2018)
Nik Sheng Ding, George Malietzis, P F C Lung, L Penez, W M Yip, S Gabe, J T Jenkins, A Hart
The body composition profile is associated with response to anti-TNF therapy in Crohn's disease and may offer an alternative dosing paradigm. Alimentary pharmacology & therapeutics 46 (9) (2017)
Nik Sheng Ding, G Malietzis, A L Hart
Editorial: anti-TNF therapy and myopenia in Crohn's disease-another step towards personalised medicine. Authors' reply. Alimentary pharmacology & therapeutics 47 (1) (2017)
S Singh, Nik Sheng Ding, null null
Letter: faecal diversion for severe perianal Crohn's disease - practical issues. Authors' reply. Alimentary pharmacology & therapeutics 42 (10) (2016)
J D Doecke, F Hartnell, P Bampton, S Bell, G Mahy, Z Grover, P Lewindon, L V Jones, K Sewell, K Krishnaprasad, R Prosser, D Marr, J Fischer, G R Thomas, J V Tehan, Nik Sheng Ding, S E Cooke, K Moss, A Sechi, P De Cruz, R Grafton, S J Connor, I C Lawrance, R B Gearry, J M Andrews, G L Radford-Smith, null null
Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study. Alimentary pharmacology & therapeutics 45 (4) (2016)
Nik Sheng Ding, A Hart, P De Cruz
Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management. Alimentary pharmacology & therapeutics 43 (1) (2015)

Nik Sheng Ding.css-eqlu8i{font-size:small;padding-left:4px;} (Nik S Ding, N S Ding, Nik Ding)

Publication Activity (10 Years)

Top Topics

Top Venues

Nik Sheng Ding (Nik S Ding, N S Ding, Nik Ding)